Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R3 (Romidepsin, Rituximab, Lenalidomide) in B-Cell Lymphomas
NCT02281279Phase 2Withdrawn
- Sponsor
- Mayo Clinic
- Start
- Oct 2016
- Primary completion
- Oct 2020
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of romidepsin and lenalidomide in B-cell non-Hodgkin lymphoma and Transformed Follicular Lymphoma (tFL), sponsored by Mayo Clinic. Primary endpoints: Maximum Tolerated Dose at 28 days and Overall Response Rate up to 5 years. Planned start Oct 2016; status: withdrawn.
02
Drugs
romidepsinlenalidomide
03
Conditions
B-cell non-Hodgkin lymphomaTransformed Follicular Lymphoma (tFL)
Beyond the preview
Go deeper on NCT02281279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02281279.